50
Participants
Start Date
July 6, 2024
Primary Completion Date
January 1, 2030
Study Completion Date
January 1, 2030
Reclaim™ DBS Therapy
DBS is indicated for bilateral stimulation of the ventral anterior limb of the internal capsule as an adjunct to medications and as an alternative to anterior capsulotomy for treatment of chronic, severe, treatment-resistant obsessive compulsive disorder (OCD) in adult patients who have failed at least three selective serotonin reuptake inhibitors (SSRIs). Medtronic received humanitarian device exemption (HDE) approval for Reclaim DBS Therapy for the management of OCD on February 19, 2009.
RECRUITING
Zucker Hillside Hospital, Queens
Lead Sponsor
Collaborators (1)
Medtronic
INDUSTRY
Northwell Health
OTHER